Carboplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding.
Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin injection administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.
CALVERT FORMULA FOR CARBOPLATIN DOSING Total Dose (mg) = (target AUC) × (GFR + 25) Note: With the Calvert formula, the total dose of carboplatin is calculated in mg, not mg/m 2.
Use: Labeled indications
- INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic…
Full indications and usage US FDA label
INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES).
There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.
Contraindications
CONTRAINDICATIONS Carboplatin injection is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds. Carboplatin injection should not be employed in patients with severe bone marrow depression or significant bleeding.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION NOTE: Aluminum reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of carboplatin injection. Single Agent Therapy Carboplatin injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m 2 intravenously on day 1 every 4 weeks (alternatively see Formula Dosing).
In general, however, single intermittent courses of carboplatin should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of: Carboplatin - 300 mg/m 2 intravenously on day 1 every 4 weeks for 6 cycles (alternatively see Formula Dosing).
Cyclophosphamide - 600 mg/m 2 intravenously on day 1 every 4 weeks for 6 cycles. For directions regarding the use and administration of cyclophosphamide please refer to its package insert (see CLINICAL STUDIES). Intermittent courses of carboplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.
Dose Adjustment Recommendations Pretreatment platelet count and performance status are important prognostic factors for severity of myelosuppression in previously treated patients. The suggested dose adjustments for single agent or combination therapy shown in the table below are modified from controlled trials in previously treated and untreated patients with ovarian carcinoma.
Blood counts were done weekly, and the recommendations are based on the lowest post-treatment platelet or neutrophil value. Platelets Neutrophils Adjusted Dose Percentages apply to carboplatin injection as a single agent or to both carboplatin and cyclophosphamide in combination. In the controlled studies, dosages were also adjusted at a lower level (50% to 60%) for severe myelosuppression.
Escalations above 125% were not recommended for these studies. (From Prior Course) > 100,000 > 2,000 125% 50 to 100,000 500 to 2,000 No Adjustment < 50,000 < 500 75% Carboplatin injection is usually administered by an infusion lasting 15 minutes or longer. No pre- or post-treatment hydration or forced diuresis is required.
Patients with Impaired Kidney Function Patients with creatinine clearance values below 60 mL/min are at increased risk of severe bone marrow suppression. In renally-impaired patients who received single agent carboplatin therapy, the incidence of severe leukopenia, neutropenia, or thrombocytopenia has been about 25% when the dosage modifications in the table below have been used.
Baseline Creatinine Clearance Recommended Dose on Day 1 41 to 59 mL/min 250 mg/m 2 16 to 40 mL/min 200 mg/m 2 The data available for patients with severely impaired kidney function (creatinine clearance below 15 mL/min) are too limited to permit a recommendation for treatment. These dosing recommendations apply to the initial course of treatment.
Subsequent dosages should be adjusted according to the patient's tolerance based on the degree of bone marrow suppression. Formula Dosing Another approach for determining the initial dose of carboplatin injection is the use of mathematical formulae, which are based on a patient's pre-existing renal function or renal function and desired platelet nadir.
Renal excretion is the major route of elimination for carboplatin (see CLINICAL PHARMACOLOGY). The use of dosing formulae, as compared to empirical dose calculation based on body surface area, allows compensation for patient variations in pretreatment renal function that might otherwise result in either underdosing (in patients with above average renal function) or overdosing (in patients with impaired renal function).
A simple formula for calculating dosage, based upon a patient's glomerular filtration rate (GFR in mL/min) and carboplatin injection target area under the concentration versus time curve (AUC in mg/mL•min), has been proposed by Calvert. In these studies, GFR was measured by 51 Cr-EDTA clearance. CALVERT FORMULA FOR CARBOPLATIN DOSING Total Dose (mg) = (target AUC) × (GFR + 25) Note: With the Calvert formula, the total dose of carboplatin is calculated in mg, not mg/m 2.
The target AUC of 4 mg/mL•min to 6 mg/mL•min using single agent carboplatin appears to provide the most appropriate dose range in previously treated patients. This study also showed a trend between the AUC of single agent carboplatin administered to previously treated patients and the likelihood of developing toxicity. % Actual Toxicity in Previously Treated Patients AUC (mg/mL∙min) Gr 3 or Gr 4 Thrombocytopenia Gr 3 or Gr 4 Leukopenia 4 to 5 16% 13% 6 to 7 33% 34% Geriatric Dosing Because renal function is often decreased in elderly patients, formula dosing of carboplatin injection based on estimates of GFR should be used in elderly patients to provide predictable plasma carboplatin injection AUCs and thereby minimize the risk of toxicity.
PREPARATION OF INTRAVENOUS SOLUTIONS Carboplatin injection is a premixed aqueous solution of 10 mg/mL carboplatin. Carboplatin aqueous solution can be further diluted to concentrations as low as 0.5 mg/mL with 5% Dextrose in Water (D 5 W) or 0.9% Sodium Chloride Injection, USP. When prepared as directed, carboplatin aqueous solutions are stable for 8 hours at room temperature (25°C).
Since no antibacterial preservative is contained in the formulation, it is recommended that carboplatin aqueous solutions be discarded 8 hours after dilution.
Dosing: Altered kidney function
Patients with Impaired Kidney Function Patients with creatinine clearance values below 60 mL/min are at increased risk of severe bone marrow suppression.
In renally-impaired patients who received single agent carboplatin therapy, the incidence of severe leukopenia, neutropenia, or thrombocytopenia has been about 25% when the dosage modifications in the table below have been used.
Baseline Creatinine Clearance Recommended Dose on Day 1 41 to 59 mL/min 250 mg/m 2 16 to 40 mL/min 200 mg/m 2 The data available for patients with severely impaired kidney function (creatinine clearance below 15 mL/min) are too limited to permit a recommendation for treatment.
Formula Dosing Another approach for determining the initial dose of carboplatin injection is the use of mathematical formulae, which are based on a patient's pre-existing renal function or renal function and desired platelet nadir.
Renal excretion is the major route of elimination for carboplatin (see CLINICAL PHARMACOLOGY ).
The use of dosing formulae, as compared to empirical dose calculation based on body surface area, allows compensation for patient variations in pretreatment renal function that might otherwise result in either underdosing (in patients with above average renal function) or overdosing (in patients with impaired renal function).
A simple formula for calculating dosage, based upon a patient's glomerular filtration rate (GFR in mL/min) and carboplatin injection target area under the concentration versus time curve (AUC in mg/mL•min), has been proposed by Calvert.
In these studies, GFR was measured by 51 Cr-EDTA clearance.
CALVERT FORMULA FOR CARBOPLATIN DOSING Total Dose (mg) = (target AUC) × (GFR + 25) Note: With the Calvert formula, the total dose of carboplatin is calculated in mg, not mg/m 2 .
This study also showed a trend between the AUC of single agent carboplatin administered to previously treated patients and the likelihood of developing toxicity. % Actual Toxicity in Previously Treated Patients AUC (mg/mL∙min) Gr 3 or Gr 4 Thrombocytopenia Gr 3 or Gr 4 Leukopenia 4 to 5 16% 13% 6 to 7 33% 34% Geriatric Dosing Because renal function is often decreased in elderly patients, formula dosing of carboplatin injection based on estimates of GFR should be used in elderly patients to provide predictable plasma carboplatin injection AUCs and thereby minimize the risk of toxicity.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness in pediatric patients have not been established (see WARNINGS, "audiologic toxicity").
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Of the 789 patients in initial treatment combination therapy studies (NCIC and SWOG), 395 patients were treated with carboplatin in combination with cyclophosphamide. Of these, 141 were over 65 years of age and 22 were 75 years or older. In these trials, age was not a prognostic factor for survival. In terms of safety, elderly patients treated with carboplatin were more likely to develop severe thrombocytopenia than younger patients.
In a combined database of 1,942 patients (414 were ≥ 65 years of age) that received single agent carboplatin for different tumor types, a similar incidence of adverse events was seen in patients 65 years and older and in patients less than 65. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Because renal function is often decreased in the elderly, renal function should be considered in the selection of carboplatin injection dosage (see DOSAGE AND ADMINISTRATION).
Dosage forms
Philippines
- ) solution for iv infusion: 10 mg/mL (150 mg/15 mL, 10 mg/mL (150 mg/15 mL and 450/45 mL, 10 mg/mL (450 mg/45 mL
- ) solution for intravenous infusion: 10 mg/mL (150 mg/15 mL, 10 mg/mL (450 mg/45 mL, 150 mg/15 mL (10 mg/mL, 150 mg/15 mL (10 mg/mL) and 450 mg/mL (10 mg/mL, 450 mg/45 mL (10 mg/mL
- ) solution for injection: 10 mg/mL (150 mg/15 mL, 10 mg/mL (450 mg/45 mL
- ) concentrate solution for iv infusion: 10 mg/mL (150 mg/15 mL and 450 mg/45 mL
- ) concentrate for solution for intravenous infusion: 10 mg/mL (150 mg/15 mL, 10 mg/mL (450 mg/45 mL
- Solution for injection: 10 mg/mL
- ) concentrate for solution for i.v. infusion: 10 mg/mL (150 mg/15 mL, 10 mg/mL (450 mg/45 mL
- ) solution for i.v. infusion: 10 mg/mL (150 mg/15 mL, 10 mg/mL (450 mg/45 mL
- Lyophilized powder for injection: 150 mg
- ) concentrate solution for infusion: 10 mg/mL (450 mg/45 mL
and 3 more forms; see the products table.
Registered products in the Philippines
71 products registered with the Food and Drug Administration (FDA) Philippines list Carboplatin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products71
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Apocartin-150Carboplatin | 150 mg/15 mL (10 mg/mL) Solution for Intravenous Infusion15 mL net content USP Type I Amber glass vial with grey bromo butyl rubber stopper and aluminum seal with white flip-off cap (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-14782 | Jan 4, 2029 | |
Apocartin-450Carboplatin | 450 mg/45 mL (10 mg/mL) Solution for Intravenous Infusion45 mL net content USP Type I Amber glass vial with grey bromo butyl rubber stopper and aluminum seal with grey flip-off cap (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-14781 | Jan 4, 2029 | |
AtrodixCarboplatin | 10 mg/mL (150 mg/15 mL) Solution for IV InfusionUSP Type I Amber Colored Vial x 15 mL (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5270-02 | Apr 16, 2029 | |
AtrodixCarboplatin | 10 mg/mL (450 mg/45 mL) Solution for IV Infusion50 mL USP Type I Amber Colored Vial x 45 mL (Net Content) (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5271-04 | Apr 16, 2029 | |
BiovinateCarboplatin | 10 mg/ mL (150 mg/ 15 mL) Solution for IV InfusionUSP Type I Tubular Amber Glass Vial x 25 mL Box of 1's | RxVAT-exempt | Beacon Pharmaceuticals LimitedBangladesh | UNILAB, Inc. | DR-XY41717 | Feb 21, 2028 | |
BiovinateCarboplatin | 10 mg/ mL (450 mg/ 45 mL) Solution for IV InfusionUSP Type I Tubular Amber Glass Vial x 50 mL Box of 1's | RxVAT-exempt | Beacon Pharmaceuticals LimitedBangladesh | UNILAB, Inc. | DR-XY41716 | Feb 21, 2028 | |
Caboo 150Carboplatin | 10 mg/mL (150 mg/15 mL) Solution for Intravenous Infusion15 mL USP Type I Amber Glass Vial with peach-colored flip-off seal (Box of 1's) | RxVAT-exempt | Neon Laboratories Ltd.India | Ambica International Corporation | DRP-5528 | Sep 23, 2029 | |
Caboo 450Carboplatin | 10 mg/mL (450 mg/45 mL) Solution for Intravenous Infusion45 mL USP Type I Amber Glass Vial with peach-colored flip-off seal (Box of 1's) | RxVAT-exempt | Neon Laboratories, Ltd.India | Diafarm, Inc.Importer: Ambica International Corporation | DRP-5527 | Sep 23, 2029 | |
Carbius-450Carboplatin | 10 mg / mL (450 mg /45 mL) Solution for IV InfusionUSP Type I Clear and Colorless Glass Vial with Pink Cover (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | IUS Bio Pharmaceutical Care Enterprises Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-12319-04 | Jul 29, 2028 | |
Carbiva-150Carboplatin | 10 mg/mL (150 mg/15 mL) Concentrate for Solution for I.V. Infusion | RxVAT-exempt | Venus Remedies LimitedIndia | 2MG Incorporated | DRP-17711 | Feb 20, 2031 | |
Carbiva-450Carboplatin | 10 mg/mL (450 mg/45 mL) Concentrate for Solution for I.V. Infusion | RxVAT-exempt | Venus Remedies Limitedindia | 2MG Incorporated | DRP-11710 | Feb 20, 2031 | |
Carbo-Health 150Carboplatin | 10 mg/mL (150mg/15mL) Solution for InjectionUSP Type I Amber Glass Vial x 20mL (15mL Net Content) placed in plastic tray Box of 1's | RxVAT-exempt | Admac LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp | DRP-8961-01 | Jul 29, 2028 | |
CarbobilCarboplatin | 10 mg/mL (150 mg/15 mL) Concentrate for Solution for Intravenous (IV) Infusion20 mL (15 mL net content) Type I amber glass vial with grey chlorobutyl rubber stopper and light blue colored flip-off seal (Box of 1's) | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon PharmaceuticalsTrader: Abil Chem Pharma Pvt Ltd. | DR-XY48295 | Aug 17, 2027 | |
CarbobilCarboplatin | 10 mg/mL (450 mg/45 mL) Concentrate for Solution for Intravenous (IV) infusion50 mL (45 mL net content) Type I amber glass vial with grey chlorobutyl rubber stopper and light blue colored flip-off seal (Box of 1's) | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon PharmaceuticalsTrader: Abil Chem Pharma Pvt Ltd. | DR-XY48292 | Aug 17, 2027 | |
CarbofonCarboplatin | 10 mg/mL (450 mg/45mL) Concentrate Solution for Infusion (IV)50 mL USP Type I Amber Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Stopper and Aluminum with Blue Flip - Off Cap (Box of 1's) | RxVAT-exempt | PT Fonko International PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc. | DRP-11528 | Mar 30, 2027 | |
CarbofonCarboplatin | 150 mg/15 mL Concentrate for Solution for Infusion (IV)20 m L Type I amber glass vial with bromobutyl rubber stopper and aluminum flip-off cap x 15 mL (Box of l's) | RxVAT-exempt | PT. Fonko International PharmaceuticalsIndonesia | Importer: Glorious Dexa Mandaya, Inc. | DRP-11570 | Mar 30, 2027 | |
CarbogetCarboplatin | 10 mg/mL (450 mg/45 mL) Solution for IV Infusion50 mL USP Type I Amber Colored Vial x 45 mL Net Content (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | GETMEDS Philippines Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5271-05 | Apr 16, 2029 | |
CarbogetCarboplatin | 150 mg/ 15 mL (10 mg/ mL) Solution for Intravenous Infusion15 mL -net content USP Type I Clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with red flip-off cap (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Getmeds Philippines Inc.Importer: 2MG Incorporated | DRP-14784-01 | Jan 4, 2029 | |
CarbogetCarboplatin | 450 mg/45 mL (10mg/mL) Solution for Intravenous Infusion45 mL -net content USP Type 1 Clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with black flip-off cap (Box of 1's) (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedPhilippines | Getmeds Philippines IncImporter: 2MG Incorporated | DRP-14783-01 | Jan 4, 2029 | |
CarbohexCarboplatin | 10 mg/mL (450 mg/45 mL) Concentrate for Solution for Intravenous (IV) Infusion50 mL (45 mL net content) Type I amber glass vial with grey chlorobutyl rubber stopper and light blue colored flip-off seal (Box of l's) | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon PharmaceuticalsTrader: Abil Chem Pharma Pvt Ltd. | DR-XY48293 | Aug 17, 2027 | |
Carbohope 150Carboplatin | 150 mg Lyophilized Powder For Injection (IV)20 mL Type I colorless vial with elastomeric rubber stopper and aluminum cap with plastic flip off (Box of 1's) | RxVAT-exempt | Glenmark Generics S.A. | Importer: Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Ltd. | DRP-11569 | Mar 30, 2027 | |
Carbol-450Carboplatin | 10 mg/mL (450 mg/45 mL) Solution for Intravenous Infusion50 mL-capacity USP Type I clear glass vial with bromobutyl rubber stopper and black aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Genace Pharma DistributorImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-9114 | Oct 6, 2030 | |
Carbonish-150Carboplatin | 10mg/mL (150mg/15mL) Solution for InjectionUSP Type I Amber Glass Vial x 20mL (15mL Net Content) placed in plastic tray (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-8961 | Jul 29, 2028 | |
Carbonish-450Carboplatin | 10 mg/mL (450 mg/45 mL) Solution for IV InfusionUSP Type I Clear and Colorless Glass vial with Pink Cover (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-12319 | Jul 29, 2028 | |
Carbopa-150Carboplatin | 10 mg/mL (150 mg/15 mL) Solution for Injection (IV Infusion)15 mL USP Type I amber tubular glass vial with grey rubber stopper and royal blue aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Accord Healthcare Limited - Philippine Branch Office | DRP-8931 | Jul 29, 2030 | |
Carbopa-450Carboplatin | 10 mg/mL (450 mg/45 mL) Solution for Injection (IV Infusion)50 mL USP Type I amber color molded glass vial with grey rubber stopper and royal blue aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Accord Healthcare Limited - Philippine Branch Office | DRP-8930 | Jul 29, 2030 | |
CarboplitinCarboplatin | 10 mg/mL (150 mg/15 mL) Solution for IV InfusionUSP Type I Amber Colored Vial x 15 mL (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambicare Pharmaceuticals Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5270-03 | Apr 16, 2029 | |
CarboplitinCarboplatin | 10 mg/mL (450 mg/45 mL) Solution for IV Infusion50 mL USP Type I Amber Colored Vial x 45 mL (Net Content) Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambicare Pharmaceuticals Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5271-03 | Apr 16, 2029 | |
CarbotinCarboplatin | 10 mg/mL (150 mg/15 mL) Solution for IV InfusionUSP Type I Amber Colored Vial x 15 mL (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Genace Pharma DistributorImporter: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5270 | Apr 16, 2029 | |
CarbotinCarboplatin | 10 mg/mL (450 mg/45 mL) Solution for IV Infusion50 mL USP Type I Amber Colored Vial x 45 mL (Net Content) (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Genace Pharma DistributorImporter: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5271 | Apr 16, 2029 | |
Carbotin 150Carboplatin | 150 mg Lyophilized Powder for Injection (IV)20 mL USP Type I clear glass vial (Box of 1's) | RxVAT-exempt | Techno Drugs LimitedBangladesh | Bridgemark Marketing | DR-XY42767 | Oct 4, 2028 | |
CarbotinolCarboplatin | 10 mg/mL (150 mg/15 mL) Solution for Injection (I.V.)Type I Amber Glass Vial with Rubber Stopper and Red Flip-off Seal x 15 mL (Box of 1's) | RxVAT-exempt | Korea United Pharm, Inc.Korea | Qualimed Pharma, Inc. | DR-XY25053 | Sep 2, 2029 | |
CarbotinolCarboplatin | 10 mg/mL (450 mg/45 mL) Solution for Injection (IV)Type I Amber Glass Vial x 45 mL with Rubber Stopper and Red Flip-off Seal (Box of 1's) | RxVAT-exempt | Korea United Pharm. Inc.Republic of Korea | Qualimed Pharma Inc. | DR-XY25052 | Mar 31, 2028 | |
Carbowind 150Carboplatin | 10 mg/mL (150mg/15mL) Solution for InjectionUSP Type I clear and colorless glass vial with pink cover (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Healthwinds Medical Trading CorpImporter: Pharmastar Int'l Trading Corp. | DRP-8961-02 | Jul 29, 2028 | |
Carbowind 450Carboplatin | 10 mg/mL (450 mg/45 mL) Solution for IV InfusionUSP Type I Clear and Colorless Glass vial with Pink Cover (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-12319-02 | Jul 29, 2028 | |
CarbozaritineCarboplatin | 10mg/mL (450mg/45mL) Solution for IV Infusion50 mL USP Type I Amber Colored Vial x 45 mL Net Content (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Oncotine Pharmaceutical Products DistributionImporter: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5271-06 | Apr 16, 2029 | |
CarbplinCarboplatin | 10 mg/mL (150 mg/15 mL) Solution for IV InfusionUSP Type I Amber Colored Vial x 15 mL Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | Diafarm Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5270-01 | Apr 16, 2029 | |
CarbplinCarboplatin | 10 mg/mL (450 mg/45 mL) Solution for IV Infusion50 mL USP Type I Amber Colored Vial x 45 mL (Net Content) (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5271-01 | Apr 16, 2029 | |
Carceplatin 150Carboplatin | 10 mg/mL (150 mg/15 mL) Solution for I.V. InjectionType I Amber Glass Vial sealed with Gray Bromobutyl Rubber Stopper and Aluminum seal with Paste color Flip-off Cap x 15 mL in White PP Tray (Box of 1's) | RxVAT-exempt | Eskayef Pharmaceuticals Limited Rupganj PlantBangladesh | Pharmakon Biotec Inc. | DRP-17812 | Mar 12, 2031 | |
Carceplatin 450Carboplatin | 10 mg/mL (450 mg/45 mL) Solution for Injection (I.V. Infusion)50 mL -capacity Type I Amber Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum seal with Paste color Flip-off Seal cap x 45 mL (net content) in White PP Tray (Box of 1's) | RxVAT-exempt | Eskayef Pharmaceuticals Limited - Rupganj PlantBangladesh | Pharmakon Biotec Inc. | DRP-17813 | Mar 12, 2031 | |
CelcarbCarboplatin | 10 mg/mL Solution for Injection (IV)USP Type I Amber Glass via x 15 mL (20 mL) Box of 1's; USP Type I Amber Glass via x 45 mL (50 mL) Box of 1's | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E Medica Inc. | DRP-2366 | Jul 30, 2031 | |
CidianumCarboplatin | 10 mg/mL (450 mg/45 mL) Solution for I.V. Infusion50 mL USP Type I Amber Colored Vial x 45 mL (Net Content) (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Pharm 518, Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5271-02 | Apr 16, 2029 | |
Cisamin-150Carboplatin | 10 mg/mL (150 mg/15 mL) Solution for Injection (IV)USP Type I Amber Moulded Glass Vial x 20 mL | RxVAT-exempt | Admac LifesciencesIndia | Detoxicare Philippines, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-6288 | Aug 13, 2030 | |
Cisamin-450Carboplatin | 10 mg/mL (450mg/45mL) Solution for Injection (I.V. Infusion)USP Type I Amber Color Moulded Glass Vial x 50 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Detoxicare Philippines, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-5902 | Dec 17, 2029 | |
DexplatinCarboplatin | 10 mg/mL (450 mg/45 mL) Solution for IV Infusion50 mL USP Type I Amber Colored Vial x 45 mL (Net Content) (Box of 1’s) | RxVAT-exempt | Getwell Pharma India Pvt. Ltd.India | Delex Pharma International, Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-5271-07 | Apr 16, 2029 | |
EmiCarbo-450Carboplatin | 10 mg/mL (450 mg/45 mL) Solution for IV InfusionUSP Type I Clear and Colorless Glass vial with Pink Cover (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-12319-03 | Jul 29, 2028 | |
HexplatinCarboplatin | 10 mg/mL (150 mg/15 mL) Concentrate for Solution for Intravenous (IV) Infusion20 mL (15 mL net content) Type I amber glass vial with grey chlorobutyl rubber stopper and light blue colored flip-off seal (Box of 1's) | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon PharmaceuticalsTrader: Abil Chem Pharma Pvt Ltd. | DR-XY48294 | Aug 17, 2027 | |
Kauplat-150Carboplatin | 150 mg / 15 mL (10 mg / mL) Solution for Intravenous Infusion15 mL - net content USP Type I Clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with red flip-off cap (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Kaufmann Pharma Inc.Importer: 2MG Incorporated | DRP-14784-02 | Jan 4, 2029 | |
Kauplat-450Carboplatin | 450mg/45mL (10mg/mL) Solution for Intravenous Infusion45 mL - net content USP Type I Clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with red flip-off cap (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Kaufmann Pharma Inc.Importer: 2MG Incorporated | DRP-14783-02 | Jan 4, 2029 | |
KemocarbCarboplatin | 10mg/mL (150 mg/15 mL and 450/45 mL) Solution for IV Infusion15mL (fill volume) in 20 mL-capacity USP Type I Clear Tubular Glass Vial (Box of 1's); 45mL (fill volume) in 50 mL-capacity USP Type I Clear Moulded Glass Vial (Box of 1's) | RxVAT-exempt | Fresenius Kabi Oncology LimitedIndia | Importer: Fresenius Kabi Philippines, Inc. | DR-XY47196 | Mar 18, 2028 | |
NaproplatCarboplatin | 10 mg/mL (150 mg/15 mL) Solution for IV InfusionType I Amber Glass Vial x 15 mL with peach flip-off seal (Box of 1's) | RxVAT-exempt | Naprod Life Sciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc. | DRP-2732 | Mar 18, 2031 | |
NaproplatCarboplatin | 10 mg/mL (450 mg/45 mL) Solution for IV InfusionType I Amber Glass Vial x 45 mL with Peach Flip-Off Seal (Box of 1's) | RxVAT-exempt | Naprod Life Sciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc. | DRP-2730 | Mar 11, 2031 | |
Neoplin-150Carboplatin | 10 mg/mL (150 mg/ 15 mL) Solution for Injection (I.V)USP Type I Molded Amber Colored Glass Vial with 20 mm Bromobutyl Flurocoated Rubber Plugs and 20 mm. Flip Off Seal x 15 mL (Box of 1 vial) | RxVAT-exempt | Drug International Limited (Unit 2)Bangladesh | Despina Pharma Inc. | DRP-15130 | May 8, 2029 | |
Neoplin-450Carboplatin | 10 mg/mL (450 mg/ 45 mL) Solution for Injection (I.V.)USP Type I Molded Amber Colored Glass Vial with 20 mm Bromobutyl Flurocoated Rubber Plugs and 20 mm Flip Off Seal x 50 mL (Net Content: 45 mL) (Box of 1 vial) | RxVAT-exempt | Drug International Limited (Unit 2)Bangladesh | Despina Pharma Inc. | DRP-15129 | May 8, 2029 | |
NeothixCarboplatin | 10 mg/mL (150 mg/ 15 mL and 450 mg/ 45 mL) Concentrate Solution for IV Infusion15 mL (fill volume) in 20 mL-capacity USP Type I Amber Vial (Box of 1's); 45 mL (fill volume) in 50 mL- capacity USP Type I Amber Vial (Box of 1's) | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | Medethix, Inc. | DRP-15511 | Jul 30, 2029 | |
NoneCarboplatin | 10 mg/mL (150 mg/15 mL and 450 mg/45 mL) Concentrate Solution for IV Infusion15 mL (fill volume) in 20 mL-capacity USP Type 1 Amber Vial (Box of 1's); 45 mL (fill volume) in 50 mL-capacity USP Type 1 Amber Vial (Box of 1's) | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-15512-01 | Jul 30, 2029 | |
NoneCarboplatin | 10 mg/mL (150 mg/15mL and 450 mg/45mL) Concentrate Solution for IV Infusion15 mL (fill volume) in 20 mL-capacity USP Type I Amber Vial (Box of 1's); 45 mL (fill volume) in 50 mL-capacity USP Type I Amber Vial (Box of 1's) | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | I.E. Medica, Inc.Importer: Medethix, Inc | DRP-15512-02 | Jul 30, 2029 | |
NoneCarboplatin | 10 mg/mL Solution for Injection (IV Infusion)15 mL Solution in 20 mL Type I Amber Glass vial in a box (150 mg/15 mL); 45 mL Solution in 50 mL Type I Amber Glass vial in a box (450 mg/45 mL) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-6206-01 | Jul 16, 2027 | |
NoneCarboplatin | 150 mg/15 mL (10 mg/mL) Solution for Intravenous Infusion15 mL net content USP Type I Clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with red flip-off cap (Box of 1's) | RxVAT-exempt | Venus Remedies Limited.India | 2MG Incorporated | DRP-14784 | Jan 4, 2029 | |
NoneCarboplatin | 450 mg/45 mL (10 mg/mL) Solution for Intravenous Infusion45 mL net content USP Type 1 Clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with black flip-off cap (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | 2MG Incorporated | DRP-14783 | Jan 4, 2029 | |
OvatinCarboplatin | 10 mg/mL (150 mg/15 mL) Solution for I.V. Infusion (I. V.)20 mL Type I clear glass vial sealed with 20 mm bromobutyl rubber stopper and black aluminum flip off seal (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Aglobal Care, Inc. | DR-XY47791 | Mar 8, 2027 | |
PlatibeneCarboplatin | 10 mg/ mL (150 mg/ 15 mL and 450 mg/ 45 mL) Concentrate Solution for IV Infusion15 mL (Fill volume) in 20 mL - capacity USP Type 1 Amber vial Box of 1's; 45 mL (Fill volume) in 50 mL - capacity USP type 1 Amber vial Box of 1's | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-15512-03 | Jul 30, 2029 | |
PlatibeneCarboplatin | 10 mg/mL Solution for Injection (IV)USP Type I Amber Glass Vial x 15 mL (20mL) (Box of 1's); USP Type I Amber Glass Vial x 45 mL (50 mL) (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-2366-01 | Jun 13, 2031 | |
PlatinovaCarboplatin | 10 mg/mL (150 mg/15 mL) Concentrate for Solution for I.V. Infusion | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon Pharmaceuticals | DRP-17602 | Feb 6, 2031 | |
PlatixonCarboplatin | 150 mg/15 mL (10 mg/mL) Solution for Intravenous Infusion5 mL net content USP Type I Clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with red flip-off cap (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Endure Medical, Inc. | DR-XY 48966 | Dec 28, 2028 | |
PlatixonCarboplatin | 450 mg/45 mL (10 mg/mL) Solution for Intravenous Infusion45 mL net content USP Type I Clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with black flip-off cap (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Endure Medical, Inc. | DR-XY 48965 | Dec 28, 2028 | |
StricarbCarboplatin | 10 mg/mL (150 mg/15 mL) Solution for Infusion (IV)20 mL (Net content: 15 mL) Type I glass vial with 20 mm brom obutyl rubber stopper and 20 mm flip-off aluminum seal (Box of 1's) | RxVAT-exempt | Mylan Laboratories Limited-OTLIndia | Importer: Mylan Philippines Inc. | DR-XY47800 | Mar 10, 2027 | |
Vexbo 450Carboplatin | 10 mg/mL (450 mg/45 mL) Solution for Injection (IV)USP Type I Amber Glass Vial with gray flip-off seal x 45 mL (Net content) in 50 mL (Box of 1’s) | RxVAT-exempt | Admac LifesciencesIndia | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY45406 | May 25, 2031 | |
WomacarbCarboplatin | 10 mg/mL Solution for Injection (IV Infusion)15 mL Solution in 20 mL Type I amber glass vial in a box (150 mg/15 mL); 45 mL Solution in 50 mL Type I amber glass vial in a box (450 mg/45 mL) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Medethix, Inc. | DRP-6206 | Jul 16, 2027 | |
(no brand name)Carboplatin | 10 mg/mL (150 mg/ 15 mL and 450 mg/ 45 mL) Concentrate Solution for IV Infusion15 mL (fill volume) in 20 mL-capacity USP Type I (fill Amber Vial (Box of 1's); 45 mL (fill volume) in 50 mL- capacity USP Type I Amber Vial (Box of 1's) | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | Medethix, Inc. | DRP-15512 | Jul 30, 2029 | |
(no brand name)Carboplatin | 150 mg/15 mL (10 mg/mL) and 450 mg/mL (10 mg/mL) Solution for Intravenous Infusion15 mL net content USP Type I Amber glass vial with grey bromo butyl rubber stopper and aluminum seal with brown flip-off cap (Box of 1's); and 45 mL net content USP Type I Amber glass vial with grey bromo butyl rubber stopper and aluminum seal with brown flip-off cap (Box of 1's) | RxVAT-exempt | Hetero Labs Limited (Unit VI)India | Camber Pharmaceuticals, Inc. | DRP-14785 | Jan 4, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
The boxed warning is shown at the top of this page.
Warnings and precautions (US label) US FDA label
WARNINGS Bone marrow suppression (leukopenia, neutropenia, and thrombocytopenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during carboplatin injection treatment and, when appropriate, until recovery is achieved. Median nadir occurs at day 21 in patients receiving single agent carboplatin.
In general, single intermittent courses of carboplatin should not be repeated until leukocyte, neutrophil, and platelet counts have recovered. Since anemia is cumulative, transfusions may be needed during treatment with carboplatin, particularly in patients receiving prolonged therapy. Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin.
Marrow suppression is also increased in patients with impaired kidney function. Initial carboplatin injection dosages in these patients should be appropriately reduced (see DOSAGE AND ADMINISTRATION) and blood counts should be carefully monitored between courses. The use of carboplatin in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimize additive effects.
Carboplatin has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiologic toxicity, and caution must be exercised when a patient receives both drugs. Clinically significant hearing loss has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents.
Carboplatin can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of emesis have been reduced by using premedication with antiemetics. Although no conclusive efficacy data exist with the following schedules of carboplatin, lengthening the duration of single intravenous administration to 24 hours or dividing the total dose over five consecutive daily pulse doses has resulted in reduced emesis.
Although peripheral neurotoxicity is infrequent, its incidence is increased in patients older than 65 years and in patients previously treated with cisplatin. Pre-existing cisplatin-induced neurotoxicity does not worsen in about 70% of the patients receiving carboplatin as secondary treatment. Loss of vision, which can be complete for light and colors, has been reported after the use of carboplatin with doses higher than those recommended in the package insert.
Vision appears to recover totally or to a significant extent within weeks of stopping these high doses. As in the case of other platinum-coordination compounds, allergic reactions to carboplatin have been reported. These may occur within minutes of administration and should be managed with appropriate supportive therapy.
There is increased risk of allergic reactions including anaphylaxis in patients previously exposed to platinum therapy (see CONTRAINDICATIONS and ADVERSE REACTIONS, Allergic Reactions). High dosages of carboplatin (more than 4 times the recommended dose) have resulted in severe abnormalities of liver function tests. Carboplatin injection may cause fetal harm when administered to a pregnant woman.
Carboplatin has been shown to be embryotoxic and teratogenic in rats. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions The renal effects of nephrotoxic compounds may be potentiated by carboplatin.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see CLINICAL STUDIES, Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer, Comparative Toxicity. ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER First Line Combination Therapy Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCIC (see CLINICAL STUDIES).
Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table. Percent Second Line Single Agent Therapy Single Agent Use for the Secondary Treatment of Ovarian Cancer: Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single agent carboplatin.
Percent Bone Marrow Thrombocytopenia <100,000/mm 3 66 62 <50,000/mm 3 33 35 Neutropenia <2,000 cells/mm 3 96 67 <1,000 cells/mm 3 82 21 Leukopenia <4,000 cells/mm 3 97 85 <2,000 cells/mm 3 71 26 Anemia <11 g/dL 90 90 <8g/dL 14 21 Infections 16 5 Bleeding 8 5 Transfusions 35 44 Gastrointestinal Nausea and vomiting 93 92 Vomiting 83 81 Other GI side effects 46 21 Neurologic Peripheral neuropathies 15 6 Ototoxicity 12 1 Other sensory side effects 5 1 Central neurotoxicity 26 5 Renal Serum creatinine elevations 6 10 Blood urea elevations 17 22 Hepatic Bilirubin elevations 5 5 SGOT elevations 20 19 Alkaline phosphatase elevations 29 37 Electrolytes loss Sodium 10 47 Potassium 16 28 Calcium 16 31 Magnesium 61 43 Other side effects Pain 44 23 Asthenia 41 11 Cardiovascular 19 6 Respiratory 10 6 Allergic 11 2 Genitourinary 10 2 Alopecia 49 2 Mucositis 8 1 In the narrative section that follows, the incidences of adverse events are based on data from 1,893 patients with various types of tumors who received carboplatin as single agent therapy. Hematologic Toxicity Bone marrow suppression is the dose-limiting toxicity of carboplatin.
Thrombocytopenia with platelet counts below 50,000/mm 3 occurs in 25% of the patients (35% of pretreated ovarian cancer patients); neutropenia with granulocyte counts below 1,000/mm 3 occurs in 16% of the patients (21% of pretreated ovarian cancer patients); leukopenia with WBC counts below 2,000/mm 3 occurs in 15% of the patients (26% of pretreated ovarian cancer patients). The nadir usually occurs about day 21 in patients receiving single agent therapy.
By day 28, 90% of patients have platelet counts above 100,000/mm 3; 74% have neutrophil counts above 2,000/mm 3; 67% have leukocyte counts above 4,000/mm 3. Marrow suppression is usually more severe in patients with impaired kidney function. Patients with poor performance status have also experienced a higher incidence of severe leukopenia and thrombocytopenia.
The hematologic effects, although usually reversible, have resulted in infectious or hemorrhagic complications in 5% of the patients treated with carboplatin, with drug related death occurring in less than 1% of the patients. Fever has also been reported in patients with neutropenia. Anemia with hemoglobin less than 11 g/dL has been observed in 71% of the patients who started therapy with a baseline above that value.
The incidence of anemia increases with increasing exposure to carboplatin. Transfusions have been administered to 26% of the patients treated with carboplatin (44% of previously treated ovarian cancer patients). Bone marrow depression may be more severe when carboplatin is combined with other bone marrow suppressing drugs or with radiotherapy.
Gastrointestinal Toxicity Vomiting occurs in 65% of the patients (81% of previously treated ovarian cancer patients) and in about one-third of these patients it is severe. Carboplatin, as a single agent or in combination, is significantly less emetogenic than cisplatin; however, patients previously treated with emetogenic agents, especially cisplatin, appear to be more prone to vomiting.
Nausea alone occurs in an additional 10% to 15% of patients. Both nausea and vomiting usually cease within 24 hours of treatment and are often responsive to antiemetic measures. Although no conclusive efficacy data exist with the following schedules, prolonged administration of carboplatin, either by continuous 24-hour infusion or by daily pulse doses given for 5 consecutive days, was associated with less severe vomiting than the single-dose intermittent schedule.
Emesis was increased when carboplatin was used in combination with other emetogenic compounds. Other gastrointestinal effects observed frequently were pain, in 17% of the patients; diarrhea, in 6%; and constipation, also in 6%. Neurologic Toxicity Peripheral neuropathies have been observed in 4% of the patients receiving carboplatin (6% of pretreated ovarian cancer patients) with mild paresthesias occurring most frequently.
Carboplatin therapy produces significantly fewer and less severe neurologic side effects than does therapy with cisplatin. However, patients older than 65 years and/or previously treated with cisplatin appear to have an increased risk (10%) for peripheral neuropathies. In 70% of the patients with pre-existing cisplatin-induced peripheral neurotoxicity, there was no worsening of symptoms during therapy with carboplatin.
Clinical ototoxicity and other sensory abnormalities such as visual disturbances and change in taste have been reported in only 1% of the patients. Central nervous system symptoms have been reported in 5% of the patients and appear to be most often related to the use of antiemetics. Although the overall incidence of peripheral neurologic side effects induced by carboplatin is low, prolonged treatment, particularly in cisplatin pretreated patients, may result in cumulative neurotoxicity.
Nephrotoxicity Development of abnormal renal function test results is uncommon, despite the fact that carboplatin, unlike cisplatin, has usually been administered without high-volume fluid hydration and/or forced diuresis. The incidences of abnormal renal function tests reported are 6% for serum creatinine and 14% for blood urea nitrogen (10% and 22%, respectively, in pretreated ovarian cancer patients).
Most of these reported abnormalities have been mild and about one-half of them were reversible. Creatinine clearance has proven to be the most sensitive measure of kidney function in patients receiving carboplatin, and it appears to be the most useful test for correlating drug clearance and bone marrow suppression. Twenty-seven percent of the patients who had a baseline value of 60 mL/min or more demonstrated a reduction below this value during carboplatin therapy.
Hepatic Toxicity The incidences of abnormal liver function tests in patients with normal baseline values were reported as follows: total bilirubin, 5%; SGOT, 15%; and alkaline phosphatase, 24%; (5%, 19%, and 37%, respectively, in pretreated ovarian cancer patients). These abnormalities have generally been mild and reversible in about one-half of the cases, although the role of metastatic tumor in the liver may complicate the assessment in many patients.
In a limited series of patients receiving very high dosages of carboplatin and autologous bone marrow transplantation, severe abnormalities of liver function tests were reported. Electrolyte Changes The incidences of abnormally decreased serum electrolyte values reported were as follows: sodium, 29%; potassium, 20%; calcium, 22%; and magnesium, 29%; (47%, 28%, 31% and 43%, respectively, in pretreated ovarian cancer patients).
Electrolyte supplementation was not routinely administered concomitantly with carboplatin, and these electrolyte abnormalities were rarely associated with symptoms. Allergic Reactions Hypersensitivity to carboplatin has been reported in 2% of the patients. These allergic reactions have been similar in nature and severity to those reported with other platinum-containing compounds, i.e., rash, urticaria, erythema, pruritus, and rarely bronchospasm and hypotension.
Anaphylactic reactions have been reported as part of postmarketing surveillance (see WARNINGS). These reactions have been successfully managed with standard epinephrine, corticosteroid, and antihistamine therapy. Injection Site Reactions Injection site reactions, including redness, swelling, and pain, have been reported during postmarketing surveillance.
Necrosis associated with extravasation has also been reported. Other Events Pain and asthenia were the most frequently reported miscellaneous adverse effects; their relationship to the tumor and to anemia was likely. Alopecia was reported (3%). Cardiovascular, respiratory, genitourinary, and mucosal side effects have occurred in 6% or less of the patients.
Cardiovascular events (cardiac failure, embolism, cerebrovascular accidents) were fatal in less than 1% of the patients and did not appear to be related to chemotherapy. Cancer-associated hemolytic uremic syndrome has been reported rarely. Malaise, anorexia, hypertension, dehydration, and stomatitis have been reported as part of postmarketing surveillance.
Adverse reaction frequency tables (US label) US FDA label
| First Line Combination Therapy Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCIC (see CLINICAL STUDIES). Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table. Percent | Second Line Single Agent Therapy Single Agent Use for the Secondary Treatment of Ovarian Cancer: Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single agent carboplatin. Percent | ||
| Bone Marrow | |||
| Thrombocytopenia | <100,000/mm 3 | 66 | 62 |
| <50,000/mm 3 | 33 | 35 | |
| Neutropenia | <2,000 cells/mm 3 | 96 | 67 |
| <1,000 cells/mm 3 | 82 | 21 | |
| Leukopenia | <4,000 cells/mm 3 | 97 | 85 |
| <2,000 cells/mm 3 | 71 | 26 | |
| Anemia | <11 g/dL | 90 | 90 |
| <8g/dL | 14 | 21 | |
| Infections | 16 | 5 | |
| Bleeding | 8 | 5 | |
| Transfusions | 35 | 44 | |
| Gastrointestinal | |||
| Nausea and vomiting | 93 | 92 | |
| Vomiting | 83 | 81 | |
| Other GI side effects | 46 | 21 | |
| Neurologic | |||
| Peripheral neuropathies | 15 | 6 | |
| Ototoxicity | 12 | 1 | |
| Other sensory side effects | 5 | 1 | |
| Central neurotoxicity | 26 | 5 | |
| Renal | |||
| Serum creatinine elevations | 6 | 10 | |
| Blood urea elevations | 17 | 22 | |
| Hepatic | |||
| Bilirubin elevations | 5 | 5 | |
| SGOT elevations | 20 | 19 | |
| Alkaline phosphatase elevations | 29 | 37 | |
| Electrolytes loss | |||
| Sodium | 10 | 47 | |
| Potassium | 16 | 28 | |
| Calcium | 16 | 31 | |
| Magnesium | 61 | 43 | |
| Other side effects | |||
| Pain | 44 | 23 | |
| Asthenia | 41 | 11 | |
| Cardiovascular | 19 | 6 | |
| Respiratory | 10 | 6 | |
| Allergic | 11 | 2 | |
| Genitourinary | 10 | 2 | |
| Alopecia | 49 | 2 | |
| Mucositis | 8 | 1 | |
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Pregnancy Category D See WARNINGS.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers It is not known whether carboplatin is excreted in human milk. Because there is a possibility of toxicity in nursing infants secondary to carboplatin treatment of the mother, it is recommended that breastfeeding be discontinued if the mother is treated with carboplatin injection.
Pharmacokinetics
The initial plasma half-life (alpha) was found to be 1.1 to 2 hours (n = 6), and the postdistribution plasma half-life (beta) was found to be 2.6 to 5.9 hours (n = 6).
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
The major route of elimination of carboplatin is renal excretion.
Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours.
There are insufficient data to determine whether biliary excretion occurs.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects.
The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates. In patients with creatinine clearances of about 60 mL/min or greater, plasma levels of intact carboplatin decay in a biphasic manner after a 30-minute intravenous infusion of 300 mg/m 2 to 500 mg/m 2 of carboplatin.
The initial plasma half-life (alpha) was found to be 1.1 to 2 hours (n = 6), and the postdistribution plasma half-life (beta) was found to be 2.6 to 5.9 hours (n = 6). The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively. The C max values and areas under the plasma concentration versus time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional.
Carboplatin, therefore, exhibits linear pharmacokinetics over the dosing range studied (300 mg/m 2 to 500 mg/m 2). Carboplatin is not bound to plasma proteins. No significant quantities of protein-free, ultrafilterable platinum-containing species other than carboplatin are present in plasma. However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 hours. All of the platinum in the 24-hour urine is present as carboplatin. Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours.
There are insufficient data to determine whether biliary excretion occurs. In patients with creatinine clearances below 60 mL/min, the total body and renal clearances of carboplatin decrease as the creatinine clearance decreases. Carboplatin dosages should therefore be reduced in these patients (see DOSAGE AND ADMINISTRATION).
The primary determinant of carboplatin injection clearance is glomerular filtration rate (GFR) and this parameter of renal function is often decreased in elderly patients. Dosing formulas incorporating estimates of GFR (see DOSAGE AND ADMINISTRATION) to provide predictable carboplatin injection plasma AUCs should be used in elderly patients to minimize the risk of toxicity.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Carboplatin 10 mg/mL, 15 mL Vial | ₱778.00–₱975.00Reference ₱887.00 | per vial | DPRI procurement range |
| Carboplatin 10 mg/mL, 45 mL Vial | ₱1,500.00–₱2,170.00Reference ₱1,600.00 | per vial | DPRI procurement range |
| Carboplatin 150 mg powder Vial | ₱750.00–₱856.00Reference ₱825.00 | per vial | DPRI procurement range |
| Carboplatin 450 mg powder Vial | ₱1,190.00–₱2,754.00Reference ₱1,600.00 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Carboplatin |
| PNF listing | Inj.: powder, 150 mg and 450 mg vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 10 mg/mL, 15 mL and 45 mL vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Carboplatin · Accord Healthcare, Inc. [US FDA-approved label, version 9, November 6, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48aa7ef3-9f44-2a08-e054-00144ff88e88
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .

